Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - IOVANCE BIOTHERAPEUTICS, INC. | tm219261d2_8k.htm |
Exhibit 16.1
March 12, 2021
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Commissioners:
We have read the statements made by Iovance Biotherapeutics, Inc. under Item 4.01 of its Form 8-K dated March 12, 2021. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Iovance Biotherapeutics, Inc. contained therein.
Very truly yours,
Marcum LLP n 750 Third Avenue n 11th Floor n New York, New York 10017 n Phone 212.485.5500 n Fax 212.485.5501 n marcumllp.com